| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 04/20/2005 | CN1197618C Mutant cholera holotoxin as an adjuvant |
| 04/19/2005 | US6881828 Chimeric polypeptide for developing vaccines for treatment of viral and tumor diseases |
| 04/19/2005 | US6881825 Identication of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and virues |
| 04/19/2005 | US6881822 Antibody for use in the treatment of tumors |
| 04/19/2005 | US6881821 Hepatitis-C virus type 4, 5, and 6 |
| 04/19/2005 | US6881723 Recombinant nucleic acid molecules are described. The molecules have a first sequence encoding a Hepatitis B virus core antigen and a second sequence encoding at least one T cell epitope inserted within the first sequence. Vectors and |
| 04/19/2005 | US6881573 Augmented solvent/detergent method for inactivating enveloped and non-enveloped viruses |
| 04/19/2005 | US6881557 Selecting variable region framework sequences from human antibody genes by comparing canonical CDR structure types for corresponding CDRs from a library of human germline antibody sequences |
| 04/19/2005 | US6881548 Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy |
| 04/19/2005 | US6881412 Safe and effective live vaccines against Flavobacterium columnare of fish were created through the induction of rifampicin resistance in a native Flavobacterium columnare isolate; these including rifampicin-resistant mutants NRRL |
| 04/19/2005 | US6881411 Method of stimulating an immune response by administration of host organisms that express intimin alone or as a fusion protein with one or more other antigens |
| 04/19/2005 | US6881410 Treatment of E. faecium infection |
| 04/19/2005 | US6881409 Compositions and methods for promoting nerve regeneration |
| 04/19/2005 | US6881406 Administering an effective amount of a Chemokine receptor (CCR4) modulating agent, in a dose effective to modulate trafficking of systemic memmory T cells |
| 04/19/2005 | US6881405 Reagents and methods for inducing an immune response to prostate specific antigen |
| 04/19/2005 | US6881200 Needleless syringe using super sonic gas flow for particle delivery |
| 04/19/2005 | CA2139507C Vaccines against aujeszky's disease and other animal diseases containing pseudorabies virus mutants |
| 04/14/2005 | WO2005033317A1 Chimeric carrier molecules for the production of mucosal vaccines |
| 04/14/2005 | WO2005033301A1 Cell activation method and cell production method and medicinal composition using the same |
| 04/14/2005 | WO2005033278A2 In vivo efficacy of ny-eso-1 plus iscom |
| 04/14/2005 | WO2005033267A2 Antigens targeted by prevalent pathogenic t cells in type 1 diabetes and uses thereof |
| 04/14/2005 | WO2005033265A2 Optimized multi-epitope constructs and uses thereof |
| 04/14/2005 | WO2005033148A1 Hypo- and hyper-acetylated meningococcal capsular saccharides |
| 04/14/2005 | WO2005033143A1 Method of stabilizing antibody and stabilized solution-type antibody preparation |
| 04/14/2005 | WO2005033134A2 Secreted protein therapeutics and uses thereof |
| 04/14/2005 | WO2005033133A2 Polynucleotides encoding erbb-2 polypeptides and kits and methods using same |
| 04/14/2005 | WO2005032587A1 Vaccine for prevention and treatment of opiate addiction |
| 04/14/2005 | WO2005032586A1 Optimized expression of hpv 45 l1 in yeast |
| 04/14/2005 | WO2005032585A1 Pharmaceutical compositions containing human papilloma virus antigens |
| 04/14/2005 | WO2005032584A2 Pertussis antigens and use thereof in vaccination |
| 04/14/2005 | WO2005032583A2 Liquid vaccines for multiple meningococcal serogroups |
| 04/14/2005 | WO2005032582A2 Immunogenic compositions for streptococcus pyogenes |
| 04/14/2005 | WO2005032572A2 Means and methods for the recruitment and identification of stem cells |
| 04/14/2005 | WO2005032545A1 Composition for treating inflammatory bowel disease |
| 04/14/2005 | WO2005032491A2 Methods and compositions for mycoplasma pneumoniae exotoxins |
| 04/14/2005 | WO2005032475A2 In vivo efficacy of ny-eso-1 plus adjuvant |
| 04/14/2005 | WO2005032470A2 Compositions and methods for treating burns |
| 04/14/2005 | WO2005032463A2 Educated nkt cells and their uses in the treatment of immune-related disorders |
| 04/14/2005 | WO2005032457A2 Vectors and methods for immunization against norwalk virus using transgenic plants |
| 04/14/2005 | WO2005032399A2 Il4 receptor antagonists for horse, dog and cat |
| 04/14/2005 | WO2005032343A2 Hedgehog signaling in prostate regeneration neoplasia and metastasis |
| 04/14/2005 | WO2005016967A3 Modified human igf-1r antibodies |
| 04/14/2005 | WO2005012494A3 Treatment of organ transplant rejection |
| 04/14/2005 | WO2005011734A3 Composition of a vegf antagonist and an anti-proliferative agent and its use for the treatment of cancer |
| 04/14/2005 | WO2005009372A3 Marek’s disease virus vaccine |
| 04/14/2005 | WO2005002512A3 Immunotherapeutic vaccine strategy |
| 04/14/2005 | WO2005001040A3 Non-lethal conditioning methods for conditioning a recipient for bone marrow transplantation |
| 04/14/2005 | WO2005000194A3 Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same |
| 04/14/2005 | WO2004112706A3 Vaccines, immunotherapeutics and methods for using the same |
| 04/14/2005 | WO2004110373A3 Therapeutic vaccine compositions for the treatment of type 1 diabetes |
| 04/14/2005 | WO2004108157B1 Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders |
| 04/14/2005 | WO2004104039A8 Tumor antigens for prevention and/or treatment of cancer |
| 04/14/2005 | WO2004101739A3 Methods for chemically synthesizing immunoglobulin chimeric proteins |
| 04/14/2005 | WO2004096989A3 Single chain antigen-binding polypeptides for polymer conjugation |
| 04/14/2005 | WO2004092212A3 Tumor antigens bfa5 for prevention and/or treatment of cancer |
| 04/14/2005 | WO2004091543A3 Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells |
| 04/14/2005 | WO2004074451A3 Loading of cells with antigens by electroporation |
| 04/14/2005 | WO2004073624A3 Contraceptive methods and compositions related to proteasomal interference |
| 04/14/2005 | WO2004067564B1 Compositions against cancer antigen liv-1 and uses thereof |
| 04/14/2005 | WO2004046168A3 Recombinant hiv-1 subclass d envelope glycoproteins |
| 04/14/2005 | WO2004037205A8 LOW DOSE METHODS FOR TREATING DISORDERS IN WHICH TNFα ACTIVITY IS DETRIMENTAL |
| 04/14/2005 | WO2004035602A3 Using heat shock proteins and alpha-2-macroglobulins to increase immune response to vaccines |
| 04/14/2005 | WO2004031105A3 Use of a33 antigens and jam-it |
| 04/14/2005 | WO2004029208A3 Cell separation compositions and methods |
| 04/14/2005 | WO2004027036A3 Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine |
| 04/14/2005 | WO2004014295A3 Tiacumicin production |
| 04/14/2005 | WO2003086453A9 Purified subfragment codifying for neuroaminidase, recombinant neuroaminidase and its use in zooprophylaxis |
| 04/14/2005 | WO2003083069A3 Activation of tumor-reactive lymphocytes via antibodies or genes recognizing cd3 or 4-1bb |
| 04/14/2005 | WO2003073983A3 Methods and compositions in treating pain using diacylglycerol kinase epsilon |
| 04/14/2005 | WO2003040340A3 Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer |
| 04/14/2005 | WO2003027228A3 Receptors and membrane-associated proteins |
| 04/14/2005 | WO2003015712A3 Methods for preparing compositions comprising heat shock proteins or alpha-2-macroglobulin |
| 04/14/2005 | WO2002079417A3 Methods of delivery of exogenous proteins to the cytosol and uses thereof |
| 04/14/2005 | US20050080468 Methods and apparatus for treating diseased tissue |
| 04/14/2005 | US20050080240 Monoclonal antibody for use as tool in prevention and treatment of viral disease; viricides |
| 04/14/2005 | US20050080233 Expression vector comprising nucleotide sequences coding bacterial outer membrane protein for use in diagnosis, prevention and treatment of microorganismal infection |
| 04/14/2005 | US20050080231 Small peptides having apoptotic activities and their applications |
| 04/14/2005 | US20050080028 Ballast administering to mammals skins; high density core overcoated with amorphous reservoir containing dna; drug delivery; containing free radical scavenger |
| 04/14/2005 | US20050080026 Nucleic acid molecule of MAP kinase interacting kinase gene family or polypeptide encoded thereby or fragment or variant of nucleic acid molecule, polypeptide or antibody, aptamer or receptor recognizing a nucleic acid molecule of gene family or polypeptide encoded thereby; treating metabolic diseases |
| 04/14/2005 | US20050079619 Using wreck and check molecular genetics as tool to identify gene sequences associated with virulence, pathogenicity and essential functioning of diploid pathogenic fungi; finding targets for antifungal agent discovery |
| 04/14/2005 | US20050079613 Downregulation of cell surface glycoproteins by a family of human ubiquitin ligases |
| 04/14/2005 | US20050079605 Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| 04/14/2005 | US20050079575 Human receptor molecules |
| 04/14/2005 | US20050079572 Expression vector comprising nuclelotide sequences coding brain acid soluble protein 1 (BASP1) for use in prevention and treatment of infection, cell proliferative, inflammatory and autoimmune disorders; gene therapy; immunotherapeutics |
| 04/14/2005 | US20050079538 polynucleotides which identify and encode human secreted proteins (SECP); expression vectors, host cells, antibodies, agonists, and antagonists; drug screening; anticarcinogenic agents |
| 04/14/2005 | US20050079209 Esters of L-carnitine of alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds |
| 04/14/2005 | US20050079186 Therapeutic vaccine peptide complex for preventing and treating disorders in mammals |
| 04/14/2005 | US20050079185 Stability; oil in water emulsions; injectable; drug delivery; aqueous solution of deactivated Mycoplasma or Circoviruses; mixture of nonionic surfactant and mineral oils; induce immunology response |
| 04/14/2005 | US20050079184 Antiinflammatory agents; anticancer agents; neurodegenerative disease; autoimmune diseases ; skin disorders; antiarthritic agents; Alzheimer's disease; antidiabetic agents |
| 04/14/2005 | US20050079180 Manipulatin of oocyte maturation and male germ cell survival |
| 04/14/2005 | US20050079178 Inhibitor of cardiac tachyarrhythmias |
| 04/14/2005 | US20050079176 Treating stress response with chemokine receptor ccr5 modulators |
| 04/14/2005 | US20050079174 Methods and compositions for immunotherapy of B cell involvement in promotion of a disease condition comprising multiple sclerosis |
| 04/14/2005 | US20050079173 Antibody that binds said inhibitor protein; interfering diagnostically or therapeutically with a wnt signal path; treatment of eye disorders, bone disorders, or tumors |
| 04/14/2005 | US20050079172 An isolated cell that expresses an antibody binding to DR4 or DR5, two members of the tumor necrosis factor (TNF) receptor super family |
| 04/14/2005 | US20050079171 Inducing immunology response; administering to mucous membranes |
| 04/14/2005 | US20050079169 Anti-FcRn antibodies for treatment of auto/allo immune conditions |
| 04/14/2005 | US20050079168 Virulence genes proteins and their use |
| 04/14/2005 | US20050079152 Immunology response against major histocompatibility complex; administering antigen mixture |
| 04/14/2005 | DE10344545A1 New isolated, truncated capsid protein C1 of beak and feather disease virus, useful in vaccines and as a diagnostic agent, and its encoding nucleic acid |